{
  "id": "fda_guidance_chunk_0367",
  "title": "Introduction - Part 367",
  "text": "question-and-answer format. In general, FDA’s guidance documents do not establish legally enforceable responsibilities. Instead, guidances describe the Agency’s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of 1 This guidance has been prepared by the Center for Drug Evaluation and Research, the Center for Biologics Evaluation and Research, the Center for Devices and Radiological Health, the Oncology Center of Excellence, and the Office of Clinical Policy at the Food and Drug Administration. 2 We note that disasters and PHEs, as those terms are used in this guidance, may include natural catastrophes (e.g., significant earthquakes) and other unanticipated, significant disruptions with the potential to substantially impact the conduct of clinical trials for medical products, including situations where the Secretary of the Department of Health and Human Services has declared a PHE under section 319 of the Public Health Service Act or has declared that circumstances exist justifying the authorization of medical products for emergency use under section 564(b) of the Federal Food, Drug, and Cosmetic Act (FD&C Act). 3 In this guidance, the terms trial participant, participant, and subject are interchangeable. Contains Nonbinding Recommendations the word should in Agency guidance means that something is suggested or recommended, but not required. II. BACKGROUND FDA recognizes that disasters and PHEs can cause major disruptions to the conduct of clinical trials of medical products. For example, disasters or PHEs can lead to population quarantines, trial site closures, travel limitations, interruptions to the supply chain for the investigational product (IP),4 or other challenges related to the type of disaster or PHE (e.g., site personnel or trial participants infected during an outbreak). These challenges can create difficulties in complying with protocol-specified procedures, including administering or using the IP or adhering to protocol-specified visits and laboratory or diagnostic testing. FDA is aware that not all trials can be initiated or continued during disasters and PHEs, and for some trials, there may be no alternative to stopping the trial earlier than planned in order to safeguard participants’ and trial staff’s safety. The determination of whether to continue a trial should be based first and foremost on ensuring that participants will continue to be able to participate safely. The determination should also consider whether the key objectives of the",
  "source": "FDA_clinical_trial_guidance.txt",
  "section_heading": "Introduction",
  "start_pos": 491904,
  "end_pos": 493440,
  "tokens": 512,
  "tags": [
    "safety",
    "regulatory",
    "clinical_trial"
  ],
  "jurisdiction": "US",
  "document_type": "fda_guidance",
  "guidance_section": "general_guidance",
  "regulatory_weight": "recommendation",
  "created_at": "2025-10-23T02:25:44.705Z"
}